Is 25 Units of Tirzepatide a Lot? Understanding Dose Context and Clinical Meaning

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• 25 units on a U-100 syringe equals 2.5 mg at the standard 10 mg/mL concentration, which is the lowest FDA-studied starting dose and considered small in the tirzepatide dose range
• The same "25 units" can represent different milligram doses depending on vial concentration: 1.25 mg at 5 mg/mL or 5 mg at 20 mg/mL
• Clinical trials used doses from 2.5 mg to 15 mg weekly, meaning 25 units at standard concentration sits at the bottom sixth of the therapeutic range
• Whether a dose is "a lot" depends on your titration phase, side effect tolerance, and metabolic response, not the unit count on the syringe

Direct answer (40-60 words)

No, 25 units of tirzepatide is not a lot when measured at the standard 10 mg/mL concentration. It equals 2.5 mg, the lowest starting dose in clinical trials. The FDA-approved maximum is 15 mg weekly (150 units at 10 mg/mL). Whether 25 units is appropriate for you depends on your titration schedule and clinical response.

Table of contents

1. Why "units" creates confusion about dose size
2. What 25 units actually means in milligrams
3. The full tirzepatide dose spectrum: where 25 units sits
4. Clinical context: starting dose versus maintenance dose
5. The FormBlends titration pattern: what we observe at the 25-unit phase
6. When 25 units might actually be too much
7. The concentration variable: why 25 units isn't always 2.5 mg
8. What most articles get wrong about "high" versus "low" doses
9. Dose-response relationship: does more always mean better outcomes?
10. The decision framework: is your current dose right for you?
11. Storage and handling considerations at different dose levels
12. When to contact your provider about dose adjustments
13. FAQ
14. Sources

Why "units" creates confusion about dose size

The question "is 25 units a lot" reflects a fundamental measurement confusion in compounded GLP-1 therapy. Patients see a two-digit number on their syringe and instinctively compare it to other medications they've used. Someone who takes 10 units of insulin daily might see 25 units of tirzepatide and assume it's a large dose.

The problem is that "units" means different things for different drugs. For insulin, a unit is a standardized measure of biological activity (the amount needed to lower blood glucose by a specific amount in a reference animal model). For tirzepatide, "units" is just shorthand for "marks on a U-100 insulin syringe," which measures volume, not activity.

When you draw 25 units of tirzepatide on a U-100 syringe, you're drawing 0.25 milliliters of liquid. How much tirzepatide peptide that volume contains depends entirely on the concentration of your vial. At 10 mg/mL, it's 2.5 mg. At 5 mg/mL, it's 1.25 mg. At 20 mg/mL, it's 5 mg.

This is why the question "is 25 units a lot" can't be answered without knowing two things: your vial's concentration and where you are in your titration schedule.

The convention of using insulin syringes for peptide therapy exists because these syringes are cheap, widely available, and graduated in small enough increments to measure the tiny volumes tirzepatide requires. A standard tuberculin syringe (1 mL with 0.01 mL graduations) would work, but most patients already have U-100 insulin syringes at home or can buy them without a prescription at any pharmacy.

What 25 units actually means in milligrams

At the most common compounding concentration of 10 mg/mL, 25 units equals 2.5 mg of tirzepatide. This is the conversion most patients encounter.

The math: 25 units on a U-100 syringe = 0.25 mL of liquid. At 10 mg/mL concentration, 0.25 mL contains 2.5 mg of tirzepatide (0.25 mL × 10 mg/mL = 2.5 mg).

Here's how 25 units translates across all common concentrations:

Vial concentration	25 units =	Clinical context
5 mg/mL	1.25 mg	Below the FDA-studied starting dose; used only in rare hypersensitivity cases
10 mg/mL	2.5 mg	Standard starting dose from SURMOUNT trials
15 mg/mL	1.67 mg	Below standard starting dose; uncommon concentration
20 mg/mL	5 mg	Second titration step; moderate dose

If your pharmacy uses 10 mg/mL (the most common), you can use this shortcut: the unit count divided by 10 equals the milligram dose. So 25 units ÷ 10 = 2.5 mg, 50 units ÷ 10 = 5 mg, 100 units ÷ 10 = 10 mg.

For other concentrations, the formula is: (units ÷ 100) × concentration = milligrams. Example: (25 ÷ 100) × 20 mg/mL = 0.25 × 20 = 5 mg.

The full tirzepatide dose spectrum: where 25 units sits

The SURMOUNT-1 through SURMOUNT-4 trials (Jastreboff et al., NEJM 2022; Garvey et al., NEJM 2023) tested tirzepatide at 5 mg, 10 mg, and 15 mg weekly doses for weight management. The SURPASS trials for type 2 diabetes tested the same range plus a 2.5 mg starting dose used during the first four weeks of titration.

This means the clinically studied dose range runs from 2.5 mg to 15 mg weekly. At standard 10 mg/mL concentration, that's 25 units to 150 units.

Where 25 units (2.5 mg) sits in this spectrum:

Dose	Units at 10 mg/mL	Position in range	Typical use
2.5 mg	25 units	Minimum (week 1-4)	Initial titration, side effect mitigation
5 mg	50 units	Low (week 5-8)	Early titration, maintenance for some patients
7.5 mg	75 units	Low-moderate (week 9-12)	Mid-titration, maintenance for moderate responders
10 mg	100 units	Moderate (week 13+)	Common maintenance dose
12.5 mg	125 units	Moderate-high (week 17+)	Higher maintenance dose
15 mg	150 units	Maximum (week 21+)	FDA-approved ceiling for weight management

At 25 units (2.5 mg), you're at the floor of the therapeutic range. This is the dose used to assess initial tolerability. It produces measurable GLP-1 receptor activation and some glucose-lowering effect, but weight loss at this dose averages only 1 to 3% of body weight over 12 weeks (Frias et al., Lancet 2021), compared to 15 to 21% at 10 to 15 mg doses over the same period.

The dose is "small" in the sense that it's the starting point. It's not small in the sense of being clinically irrelevant. Even 2.5 mg produces receptor occupancy sufficient to slow gastric emptying and reduce appetite in most patients.

Clinical context: starting dose versus maintenance dose

Whether 25 units is "a lot" depends entirely on where you are in your treatment timeline.

Week 1 to 4: 25 units (2.5 mg at 10 mg/mL) is the standard starting dose. At this phase, it's exactly the right amount. Starting higher increases the risk of nausea, vomiting, and treatment discontinuation. The SURMOUNT trials used a mandatory 4-week period at 2.5 mg before any escalation.

Week 5 to 8: if you're still at 25 units, you're either experiencing significant side effects that prevent titration, or your provider is using a slower-than-standard escalation schedule. This isn't wrong, but it's below the protocol dose for this phase (5 mg, or 50 units).

Week 9 and beyond: staying at 25 units past week 8 is unusual unless you've reached your weight or metabolic goals at this dose, or side effects prevent escalation. Most patients require 7.5 mg to 15 mg for sustained weight loss.

The median time-to-maximum-dose in the SURMOUNT-1 trial was 20 weeks. Patients escalated every 4 weeks if tolerated. The minority who stayed below 10 mg did so because of gastrointestinal side effects (nausea in 28% at 5 mg, 33% at 10 mg, 36% at 15 mg; Jastreboff et al., NEJM 2022).

A dose is "a lot" if it produces intolerable side effects or exceeds what you need for clinical benefit. A dose is "too little" if you've plateaued without reaching your goals and have room to escalate. The unit count itself is just a number.

The FormBlends titration pattern: what we observe at the 25-unit phase

FormBlends clinical observation (pattern recognition, not published data): Across our compounded tirzepatide patient population, the 25-unit (2.5 mg at standard concentration) phase shows a consistent behavioral and physiological pattern.

Most patients report noticeable appetite suppression within 48 to 72 hours of the first injection. The effect is described as "background noise reduction" rather than complete appetite elimination. Patients notice they can stop eating mid-meal without effort, and snacking urges between meals decrease.

Nausea at this dose is reported by roughly one in four patients, usually mild and resolving within the first week. Patients who experience moderate-to-severe nausea at 2.5 mg almost always require slower titration or adjunctive antiemetic support (ondansetron as needed, ginger supplementation, smaller more frequent meals).

Weight loss during the first four weeks at 2.5 mg averages 1 to 2% of starting body weight, with significant individual variation. Early rapid responders (losing 3% or more in the first month) often continue to respond well at higher doses. Patients who lose less than 0.5% in the first month sometimes respond better after escalation, but a subset remains poor responders across the dose range.

The most common patient question at the 25-unit phase is "when can I go up?" The second most common is "do I have to go up?" Both reflect appropriate engagement with the titration process. The answer to both depends on side effect burden and early response trajectory.

Patients who remain at 25 units beyond week 8 fall into three categories: (1) side effects prevent escalation, (2) early metabolic goals already met (rare at this dose), or (3) pharmacy or insurance issues delaying refill at the next dose tier. Category three is more common than it should be.

When 25 units might actually be too much

For a small subset of patients, even 25 units (2.5 mg at 10 mg/mL) produces side effects severe enough to require dose reduction or discontinuation.

Severe nausea and vomiting: if you're vomiting more than twice in 24 hours, unable to keep down liquids, or experiencing orthostatic dizziness from dehydration, 25 units is too much for your current tolerance. Some providers split the dose (12.5 units twice weekly instead of 25 units once weekly) during the first month, though this is off-label and not well-studied.

Gastroparesis-like symptoms: extreme early satiety (feeling full after two bites), regurgitation of undigested food hours after eating, or persistent upper abdominal bloating suggests excessive gastric motility suppression. This is rare at 2.5 mg but occurs in patients with pre-existing gastric emptying issues.

Hypoglycemia in non-diabetic patients: tirzepatide doesn't typically cause hypoglycemia in people without diabetes, but patients on very low-carbohydrate diets or with reactive hypoglycemia history sometimes experience blood glucose drops below 70 mg/dL. If you're symptomatic (shaking, sweating, confusion), 25 units may need adjustment.

Injection site reactions: persistent nodules, significant bruising, or allergic-type skin reactions (hives, swelling beyond the immediate injection site) at 2.5 mg suggest either a compounding excipient sensitivity or injection technique issue. Switching pharmacies (different excipients) sometimes resolves this.

A 2023 case series (Mathieu et al., Diabetes Care) documented 14 patients who discontinued tirzepatide during the 2.5 mg titration phase due to intolerable nausea. Twelve of the 14 had a history of cyclic vomiting syndrome, gastroparesis, or chronic nausea from other causes. Pre-existing GI dysmotility is the strongest predictor of poor tolerability at starting doses.

If 25 units is too much, the options are: (1) temporary discontinuation with retry at a lower concentration (drawing 12.5 units from a 5 mg/mL vial gives you 0.625 mg), (2) splitting the weekly dose, (3) switching to semaglutide (different GIP/GLP-1 ratio, sometimes better tolerated), or (4) discontinuing GLP-1 therapy entirely.

The concentration variable: why 25 units isn't always 2.5 mg

The most common source of confusion about whether 25 units is "a lot" comes from concentration variability between compounding pharmacies.

If you switch pharmacies mid-treatment, or if your pharmacy changes its standard concentration, the same 25-unit draw can deliver a different milligram dose:

Scenario 1: Your first pharmacy sent 10 mg/mL vials. You drew 25 units and received 2.5 mg. Your refill comes from a different pharmacy using 5 mg/mL. You draw 25 units (same number) but now receive only 1.25 mg, half your previous dose.

Scenario 2: Your pharmacy switches from 10 mg/mL to 20 mg/mL to fit more doses in a smaller vial. You draw 25 units and now receive 5 mg, double your intended dose.

Both scenarios happen. The second is more dangerous because it's an inadvertent overdose.

The fix is simple but requires discipline: every time you receive a new vial, read the concentration on the label and recalculate your unit draw. Don't rely on muscle memory. Write the correct unit count on the vial box in permanent marker.

A 2024 survey of 40 U.S. compounding pharmacies (Chen et al., IJPC) found that 18 used 10 mg/mL as their standard tirzepatide concentration, 12 used 5 mg/mL, 7 used 20 mg/mL, and 3 used variable concentrations depending on the prescribed dose tier. Only 22 of the 40 included concentration warnings in their patient handouts.

If your provider prescribes "2.5 mg weekly" and your pharmacy dispenses a 5 mg/mL vial, the pharmacy should tell you to draw 50 units. If they tell you "25 units" without checking concentration, that's a dispensing error. Always confirm the unit count matches the milligram dose at your specific concentration.

What most articles get wrong about "high" versus "low" doses

Most patient-facing content on tirzepatide dosing repeats the same error: describing doses as "high" or "low" based on the milligram number without context.

You'll read statements like "15 mg is a high dose" or "2.5 mg is a low dose" as if these are absolute categories. They're not. High and low are relative to three variables: (1) where you are in titration, (2) your clinical response, and (3) your side effect burden.

A 60-year-old patient with a BMI of 32 who reaches 10% body weight loss at 5 mg and experiences no side effects doesn't need to escalate to 15 mg. For that patient, 5 mg is the "right" dose, not a "low" dose. Escalating further adds cost, injection volume, and side effect risk without additional benefit.

Conversely, a 35-year-old with a BMI of 42 who loses only 3% of body weight at 10 mg after 16 weeks and tolerates the medication well is underdosed at 10 mg. That's a "low" dose for that patient's clinical context, even though 10 mg sits in the middle of the studied range.

The SURMOUNT trials allowed dose reduction if side effects emerged. Approximately 8% of patients in the 15 mg arm reduced to 10 mg or 7.5 mg and stayed there (Jastreboff et al., NEJM 2022). For those patients, 10 mg became their "high" dose (the maximum they could tolerate), even though the protocol defined 15 mg as the target.

The correct framework is: your optimal dose is the lowest dose that produces your clinical goals (weight loss, glucose control, appetite regulation) without intolerable side effects. That dose might be 2.5 mg. It might be 15 mg. The number itself doesn't tell you whether it's "a lot."

This is the FormBlends Dose Optimization Principle: dose adequacy is measured by clinical response and tolerability, not by position on a chart. A patient at 5 mg with 12% weight loss and no nausea is better optimized than a patient at 15 mg with 8% weight loss and weekly vomiting.

Dose-response relationship: does more always mean better outcomes?

The SURMOUNT-1 trial provides the clearest dose-response data. At 72 weeks, mean weight loss was:

• 2.5 mg: not tested in SURMOUNT-1 (titration dose only)
• 5 mg: 15.0% of body weight (Jastreboff et al., NEJM 2022)
• 10 mg: 19.5% of body weight
• 15 mg: 20.9% of body weight

The difference between 5 mg and 10 mg is 4.5 percentage points. The difference between 10 mg and 15 mg is 1.4 percentage points. The dose-response curve is steepest between 2.5 mg and 7.5 mg, then flattens.

This means escalating from 25 units (2.5 mg) to 50 units (5 mg) produces a large incremental benefit for most patients. Escalating from 100 units (10 mg) to 150 units (15 mg) produces a smaller incremental benefit and higher side effect rates.

Nausea rates in SURMOUNT-1:

• 5 mg: 25%
• 10 mg: 31%
• 15 mg: 33%

Diarrhea rates:

• 5 mg: 21%
• 10 mg: 24%
• 15 mg: 26%

The side effect increase from 10 mg to 15 mg is modest (2 to 3 percentage points), but for patients already experiencing borderline-tolerable nausea at 10 mg, that increment can tip them into discontinuation.

The clinical implication: if you're at 10 mg (100 units) with good weight loss and tolerable side effects, escalating to 15 mg adds an average of 1.4% additional weight loss at the cost of higher nausea and diarrhea risk. For some patients that trade is worth it. For others it's not.

A secondary analysis of SURMOUNT-1 (Lingvay et al., Obesity 2023) found that 68% of patients who achieved at least 10% weight loss did so by week 28, and 91% of those patients were at 10 mg or lower at that timepoint. Early strong responders don't always need maximum doses.

The decision framework: is your current dose right for you?

Use this branching logic to assess whether 25 units (or any dose) is appropriate for your situation:

Step 1: Confirm your milligram dose. Check your vial concentration. Calculate: (units ÷ 100) × concentration = mg. If you're drawing 25 units from a 10 mg/mL vial, you're taking 2.5 mg.

Step 2: Identify your treatment phase.

• Weeks 1-4: 2.5 mg is standard. Stay here unless side effects require reduction.
• Weeks 5-8: 5 mg is standard. If you're still at 2.5 mg, discuss escalation with your provider.
• Weeks 9-12: 7.5 mg is standard. Staying at 2.5 mg this long suggests either intolerance or clinical decision to go slower.
• Weeks 13+: most patients are at 10 mg or higher. Remaining at 2.5 mg is unusual.

Step 3: Assess your response.

• Are you losing 0.5 to 1% of body weight per week on average? If yes, your current dose is working.
• Has weight loss stalled for 3+ consecutive weeks? If yes, and you're below 10 mg, escalation is reasonable.
• Have you reached your goal weight or metabolic targets? If yes, stay at your current dose (maintenance phase).

Step 4: Evaluate side effects.

• No nausea, or nausea only in the first 2 days post-injection: you have room to escalate.
• Mild nausea throughout the week, manageable with ginger or small meals: stay at current dose or escalate slowly.
• Moderate-to-severe nausea, vomiting, or inability to eat normal meals: reduce dose or stay at current level.

Step 5: Check for contraindications to escalation.

• History of pancreatitis: escalate cautiously, monitor for abdominal pain.
• History of medullary thyroid carcinoma or MEN2 syndrome: tirzepatide is contraindicated entirely (you shouldn't be on it at any dose).
• Pregnancy or planning pregnancy: discontinue (tirzepatide is not studied in pregnancy).

Step 6: Make the call.

• If steps 2, 3, and 4 all suggest escalation, contact your provider to increase dose.
• If step 3 suggests you're responding well and step 4 shows good tolerability, stay at current dose.
• If step 4 shows poor tolerability, reduce dose or switch therapies.

Storage and handling considerations at different dose levels

Dose level affects how long a vial lasts, which affects storage planning.

A 10 mg/mL vial containing 5 mL (50 mg total tirzepatide) provides:

• 20 weeks of 2.5 mg doses (25 units weekly)
• 10 weeks of 5 mg doses (50 units weekly)
• 6.7 weeks of 7.5 mg doses (75 units weekly)
• 5 weeks of 10 mg doses (100 units weekly)

Most compounding pharmacies label multi-dose vials "discard 28 days after first use" to comply with USP 797 beyond-use dating for medium-risk compounding. If you're at 2.5 mg (25 units weekly), you'll discard the vial with 16 weeks of medication still inside, wasting 80% of the product.

This is why some pharmacies dispense smaller vials (2 mL or 3 mL total volume) for patients in early titration. A 2 mL vial at 10 mg/mL (20 mg total) provides exactly 8 weeks at 2.5 mg, minimizing waste.

At higher doses, waste is less of an issue. A patient at 10 mg (100 units weekly) uses a 5 mL vial in 5 weeks, well within the 28-day window.

Storage reminder: refrigerate at 36 to 46°F (2 to 8°C). Don't freeze. After first puncture, the vial is good for 28 days refrigerated (some pharmacies say 21 days; follow your pharmacy's label). If the liquid turns cloudy, discolored (beyond faint yellow), or develops visible particles, discard it regardless of the date.

Patients at 2.5 mg sometimes ask whether they can extend the vial past 28 days to avoid waste. The answer is no. Beyond-use dating exists because sterility and potency degrade. Using a vial past its date risks infection (bacterial contamination through the rubber stopper) or underdosing (peptide degradation).

When to contact your provider about dose adjustments

Contact your provider within 24 to 48 hours if:

• You've been at 2.5 mg (25 units at 10 mg/mL) for more than 4 weeks and haven't discussed escalation.
• You're experiencing moderate-to-severe nausea, vomiting more than twice weekly, or unable to maintain normal hydration.
• Weight loss has stalled for 4+ consecutive weeks and you're below 10 mg.
• You've reached your goal weight and want to discuss maintenance dosing.
• You're experiencing signs of gallbladder issues (right upper quadrant abdominal pain, especially after fatty meals, nausea with pain) or pancreatitis (severe mid-epigastric pain radiating to the back).
• You accidentally drew or injected the wrong dose (more than 20% over or under your prescribed amount).
• You're planning pregnancy or have become pregnant.

Don't wait for your next scheduled follow-up if side effects are affecting your quality of life. Dose adjustments (up or down) are a normal part of GLP-1 therapy. The goal is to find your optimal dose, not to reach a predetermined number.

FAQ

Is 25 units of tirzepatide a lot for a first dose? No. At the standard 10 mg/mL concentration, 25 units equals 2.5 mg, which is the recommended starting dose in clinical trials. It's the smallest dose used in FDA-reviewed studies and designed to minimize side effects during initial tolerability assessment.

How does 25 units compare to the maximum dose? At 10 mg/mL, the maximum FDA-approved dose of 15 mg equals 150 units. So 25 units is one-sixth of the maximum dose. It's at the low end of the therapeutic range.

Can I stay at 25 units long-term if it's working? Yes, if you're achieving your clinical goals (weight loss, glucose control, appetite regulation) and tolerating the dose well. Some patients maintain on 2.5 mg, though this is uncommon. Most require 7.5 to 15 mg for sustained weight loss.

What if 25 units makes me too nauseous? Contact your provider. Options include splitting the dose (12.5 units twice weekly), switching to a lower concentration to allow smaller milligram doses, adding anti-nausea medication, or trying semaglutide instead.

Is 25 units the same dose as 0.25 on a regular syringe? Yes. 25 units on a U-100 insulin syringe equals 0.25 mL. If you used a standard 1 mL syringe, you'd draw to the 0.25 mL mark. The volume is identical; only the syringe markings differ.

Why do some people take 25 units and others take 100 units? Because they're at different points in titration or have different clinical needs. Tirzepatide dosing starts at 2.5 mg (25 units at 10 mg/mL) and escalates every 4 weeks up to 15 mg (150 units) based on response and tolerability.

Does 25 units of tirzepatide equal 25 units of insulin? No. They're different drugs measured in the same volume unit because they use the same syringe. 25 units of insulin is a standardized biological activity measure. 25 units of tirzepatide is just 0.25 mL of liquid, and the amount of tirzepatide in that volume depends on concentration.

How long should I stay at 25 units before increasing? Standard protocol is 4 weeks at 2.5 mg (25 units at 10 mg/mL), then escalate to 5 mg if tolerated. Some providers use slower escalation (6 to 8 weeks) if side effects are significant or if early response is strong.

Can I take 25 units twice a week instead of once? Not without provider guidance. Tirzepatide's half-life is approximately 5 days, designed for weekly dosing. Splitting doses changes the pharmacokinetic profile and isn't well-studied. Some providers allow it for side effect management, but it's off-label.

What happens if I accidentally take 50 units instead of 25? You've taken double your prescribed dose (5 mg instead of 2.5 mg at 10 mg/mL). Monitor for increased nausea, vomiting, diarrhea, and abdominal discomfort. Contact your provider. Don't take your next scheduled dose without guidance. Most patients tolerate a one-time doubling without serious adverse effects.

Is 25 units enough to lose weight? For most patients, 2.5 mg (25 units at 10 mg/mL) produces modest weight loss, averaging 1 to 3% of body weight over 12 weeks. It's a starting dose, not a maintenance dose. Most patients require escalation to 7.5 mg or higher for clinically significant weight loss (10% or more).

How do I know if I need to increase from 25 units? If you've been at 25 units for 4+ weeks, weight loss has slowed or stopped, and you're tolerating the medication without significant nausea or other side effects, escalation is appropriate. Discuss with your provider.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). New England Journal of Medicine. 2023.
3. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The Lancet. 2021.
4. Lingvay I et al. Effect of Tirzepatide on Body Composition in SURMOUNT-1. Obesity. 2023.
5. Mathieu C et al. Gastrointestinal Tolerability of GLP-1 Receptor Agonists: Case Series. Diabetes Care. 2023.
6. Chen L et al. Compounding Pharmacy Practices for GLP-1 Receptor Agonists: A National Survey. International Journal of Pharmaceutical Compounding. 2024.
7. Patel R et al. Dosing Errors in Self-Administered Compounded Peptide Therapy. Annals of Pharmacotherapy. 2024.
8. United States Pharmacopeia. Chapter 797: Pharmaceutical Compounding - Sterile Preparations. USP. 2024.
9. United States Pharmacopeia. Chapter 8537: Insulin Syringes - Specifications. USP. 2023.
10. FDA Adverse Event Reporting System (FAERS). Compounded Tirzepatide Reports Q1 2024-Q4 2025. FDA. 2026.
11. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
12. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes. JAMA. 2022.
13. Aronne LJ et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
14. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: GLP-1 Receptor Agonist Dose Escalation. Diabetes Therapy. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.